Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

CY-2010: NCI will start a Phase I/II trial

August 1, 1994 7:00 AM UTC

Cytel Corp. (CYTL), San Diego Product: CY-2010 peptide derived from the MAGE-3 tumor marker, which directs cytotoxic T lymphocytes to cells bearing the antigen. Indication: Solid tumors including mela...